Eisai Co., Ltd. and Biogen Inc. have announced promising real-world findings on the long-term treatment persistence of their Alzheimer's drug, lecanemab. The analysis, presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, revealed that most patients continue treatment beyond the initial 18 months. The study, utilizing the PurpleLab CLEAR Claims database, assessed 10,763 individuals in the […]















